What dose of triamcinolone acetonide (Kenalog) and lidocaine should be injected into the distal biceps tendon bursa?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Distal Biceps Tendon Bursa Injection Dosing

Based on standard musculoskeletal injection practices and FDA labeling, inject 2.5-5 mg of triamcinolone acetonide (Kenalog-10: 0.25-0.5 mL of 10 mg/mL concentration) mixed with 1-2 mL of 1% lidocaine into the distal biceps tendon bursa.

Corticosteroid Dosing

The FDA label for Kenalog-10 specifies that for smaller joints and bursal injections, the initial dose ranges from 2.5 mg to 5 mg 1. The distal biceps bursa qualifies as a smaller anatomical structure, placing it in this lower dosage range rather than the 5-15 mg range reserved for larger joints.

Key dosing principles from the FDA label:

  • Use the lowest effective concentration and dose
  • The injection site and volume must be carefully considered due to potential for cutaneous atrophy
  • Multiple sites should be separated by at least one centimeter
  • Strict aseptic technique is mandatory 1

Lidocaine Dosing

For local anesthetic, 1-2 mL of 1% lidocaine is appropriate for this small bursal space. The FDA label for lidocaine indicates that the lowest concentration and smallest dose producing the desired effect should be used 2. For adults, maximum safe doses are 4.5 mg/kg without epinephrine and 7.0 mg/kg with epinephrine 3.

Practical calculation: 1-2 mL of 1% lidocaine = 10-20 mg, well below toxic thresholds for any adult patient.

Clinical Practice Patterns

Survey data from sports medicine physicians shows that for bursal injections, most practitioners use:

  • Triamcinolone (50-56% of physicians) or methylprednisolone (25-29%)
  • Doses of 21-40 mg for larger structures, though 36% use >40 mg for at least one injection type
  • Lidocaine as the preferred local anesthetic (79-87% of physicians) 4

However, these higher doses apply to larger bursae (subacromial, trochanteric). The distal biceps bursa is considerably smaller, warranting the lower end of the dosing spectrum.

Injection Technique Considerations

Preparation and administration:

  • Shake the Kenalog vial before use to ensure uniform suspension
  • Inspect for clumping or granular appearance (agglomeration) - discard if present
  • Use a tuberculin syringe with 23-25 gauge needle for accuracy 1
  • Inject directly into the bursal space, not surrounding tissues
  • Total injectate volume should be 1.5-2.5 mL to avoid overdistension of this small bursa

Ultrasound guidance is strongly recommended for accurate needle placement and to avoid injecting into the tendon substance itself, which could lead to tendon weakening.

Safety Considerations

Critical warnings:

  • Avoid injecting into the tendon substance - this may cause tendon atrophy or rupture
  • Do not inject if active infection is present
  • Local overdose can result in atrophy, pigmentary changes, and telangiectasias 5
  • The distal biceps region has limited soft tissue coverage, increasing atrophy risk

Contraindications to corticosteroid injection:

  • Active infection at the site
  • Previous hypersensitivity to triamcinolone
  • Uncontrolled diabetes, heart failure, or severe hypertension 5

Alternative Formulations

If using Kenalog-40 (40 mg/mL concentration) instead of Kenalog-10, inject only 0.06-0.125 mL to achieve the same 2.5-5 mg dose. However, Kenalog-10 is preferred for small bursal injections as it allows more accurate dosing and better distribution within the limited space.

For patients with true lidocaine allergy, alternatives include:

  • Ester-type local anesthetics
  • 1% diphenhydramine
  • Bacteriostatic normal saline 3

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.